Fluzone® High-Dose Influenza Vaccine
作者： Corwin A. Robertson , Carlos A. DiazGranados , Michael D. Decker , Ayman Chit , Monica Mercer
DOI: 10.1080/14760584.2016.1254044
关键词:
摘要: ABSTRACTIntroduction: Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin each strain, which four times the content standard-dose vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed US since December 2009 and Canada February 2016.Areas covered: In this review, we summarize postlicensure studies on immunogenicity, safety, effectiveness estimates its cost-effectiveness adults. We also discuss potential application 50–64 years age individuals who may respond poorly to vaccines.Expert commentary: Multiple conducted 2004 have consistently shown that, adults, induces substantially greater antibody responses better protection against influenza-associated hos...
sci-hub.se 参考文章(63)
H Matzkin, E Nili, Accidental tenfold overdose of influenza vaccine: a clinical and serological study. Israel journal of medical sciences. ,vol. 20, pp. 411- 415 ,(1984)
Natasha B. Halasa, Bipin N. Savani, Ishan Asokan, Adetola Kassim, Rhea Simons, Chelsey Summers, John Bourgeois, Carey Clifton, Leigh Ann Vaughan, Catherine Lucid, Li Wang, Christopher Fonnesbeck, Madan Jagasia, Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients Biology of Blood and Marrow Transplantation. ,vol. 22, pp. 528- 535 ,(2016) , 10.1016/J.BBMT.2015.12.003
Andrew J. Dunning, Carlos A. DiazGranados, Timothy Voloshen, Branda Hu, Victoria A. Landolfi, H. Keipp Talbot, Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial Clinical and Vaccine Immunology. ,vol. 23, pp. 228- 235 ,(2016) , 10.1128/CVI.00604-15
Stefan Gravenstein, Roshani Dahal, Pedro L Gozalo, H Edward Davidson, Lisa F Han, Monica Taljaard, Vincent Mor, A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale: Clinical Trials. ,vol. 13, pp. 264- 274 ,(2016) , 10.1177/1740774515625976
Carlos A. DiazGranados, Andrew J. Dunning, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, David P. Greenberg, Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults Clinical Infectious Diseases. ,vol. 62, pp. 1092- 1099 ,(2016) , 10.1093/CID/CIW085
Nigel W Crawford, Julie E Bines, Jenny Royle, Jim P Buttery, Optimizing immunization in pediatric special risk groups. Expert Review of Vaccines. ,vol. 10, pp. 175- 186 ,(2011) , 10.1586/ERV.10.157
Stefan Gravenstein, Monica Taljaard, Pedro Gozalo, Roshani Dahal, H Edward Davidson, Lisa Han, Jessica Ogarek, Vincent Mor, None, Relative Effect of High-Dose Influenza Vaccination on Hospitalizations of Older Adults in United States Nursing Homes: Results From a Cluster-Randomized Controlled Trial Open Forum Infectious Diseases. ,vol. 2, ,(2015) , 10.1093/OFID/OFV130.08
Stacy L. Davlin, Lenee Blanton, Krista Kniss, Desiree Mustaquim, Sophie Smith, Natalie Kramer, Jessica Cohen, Charisse Nitura Cummings, Shikha Garg, Brendan Flannery, Alicia M. Fry, Lisa A. Grohskopf, Joseph Bresee, Teresa Wallis, Wendy Sessions, Rebecca Garten, Xiyan Xu, Anwar Isa Abd Elal, Larisa Gubareva, John Barnes, David E. Wentworth, Erin Burns, Jacqueline Katz, Daniel Jernigan, Lynnette Brammer, Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine Morbidity and Mortality Weekly Report. ,vol. 65, pp. 567- 575 ,(2016) , 10.15585/MMWR.MM6522A3
J. S. Bresee, D. K. Shay, N. J. Cox, M. G. Thompson, E. Burns, P. Y. Cheng, H. Zhou, C. B. Bridges, Estimates of deaths associated with seasonal influenza - United States, 1976-2007. Morbidity and Mortality Weekly Report. ,vol. 59, pp. 1057- 1062 ,(2010)
, Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†. Canada communicable disease report = Releve des maladies transmissibles au Canada. ,vol. 37, pp. 1- 68 ,(2011) , 10.14745/CCDR.V37I00A06